Hodgkin Lymphoma   

What about if the patient has mediastinal disease and ISRT is not an option?

Per the NCCN guideline for HR HD, if treated per OEPA-COPDAC, you can omit ISRT. This patient received treatment per AHOD1331, which recommends ISRT f...

DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.

Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

Does the stage at diagnosis affect your decision?

Initial tumor size:18 cm. Partial response was achieved after cycle 2 and cycle 6 of chemotherapy. Complete response (Deauville 2, size: 6 cm) was ach...

If so, what treatment regimen would you recommend?

Do you use a cutoff of 10 cm? Do you measure the size of the largest node or measure the largest conglomerate or measure the total length of the entir...

What agents would have sufficient efficacy overlap to treat both?

Are there situations in which a Deauville 3 would cause you to escalate therapy?

How does your treatment approach vary depending on the underlying predisposition?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

What would you recommend in the case of ABVD or BEACOPP?

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  

Are there other regimens you employ for patients unsuitable for standard chemotherapy?

The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2,  the clinical staging/risk classification did not include ESR, b...

Have the RAPID or CALGB 5064 studies changed your treatment approach?

NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario.  What factors help your decision making?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

There are multiple regimens including IGEV and most recently reported results of BEGEV without preference on NCCN guidelines.

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Although not approved, for example, are you every using AVD-nivolumab?

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?